Superworth

Zentalis Pharmaceuticals EPS ZNTL

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$1.95
Latest quarter, Q2 FY26
−$0.59
Fiscal year 2025
−$1.90

Zentalis Pharmaceuticals' earnings per share was −$1.95 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.59.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.90n/a
FY2024−$2.33n/a
FY2023−$4.57n/a
FY2022−$4.56n/a
FY2021−$3.78n/a
FY2020−$5.58−100%
FY2019$16786997.40n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.59n/a−$1.95
Q1 FY26−$0.50n/a−$1.73
Q4 FY25−$0.49n/a−$1.90
Q3 FY25−$0.37n/a−$2.08
Q2 FY25−$0.37n/a−$2.27
Q1 FY25−$0.67−579%−$3.14
Q4 FY24−$0.67n/a−$2.33
Q3 FY24−$0.56n/a−$2.52
Q2 FY24−$1.24n/a−$2.75
Q1 FY24$0.14n/a−$3.36
Q4 FY23−$0.86n/a−$4.57
Q3 FY23−$0.79n/a−$4.66

Against its peers

Companies in Drug Manufacturers - General nearest Zentalis Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ZNTLZentalis Pharmaceuticals−$1.95
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ARVNArvinas$0.16
ATNMActinium Pharmaceuticals$0.36
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Zentalis Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.